Company news

Karyopharm Therapeutics Inc. news in 2022

Karyopharm Therapeutics Inc.'s news releases, calls and decks from 2022, newest first.

View company

Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022

December 11, 2022

Karyopharm Announces $165 Million Private Placement

December 4, 2022

Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

November 2, 2022

Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

October 31, 2022

Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

August 3, 2022

Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy

July 20, 2022

Karyopharm Granted Regulatory Designations for Eltanexor for the Treatment of Myelodysplastic Syndromes

July 19, 2022

Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma

May 19, 2022

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2022 Hybrid Congress

May 11, 2022

Karyopharm to Report First Quarter 2022 Financial Results on May 5, 2022

April 27, 2022

Karyopharm Announces Selinexor Data to be Presented at the 2022 American Society of Clinical Oncology Annual Meeting

April 26, 2022

Karyopharm Announces Further Transition of Co-Founders Sharon Shacham PhD, MBA and Michael Kauffman, MD, PhD and appointment of Reshma Rangwala, MD, PhD as Chief Medical Officer

March 28, 2022

Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer

March 15, 2022

Karyopharm Names New Head of Investor Relations

March 13, 2022

Karyopharm Provides U.S. Regulatory Update on Selinexor in Advanced or Recurrent Endometrial Cancer

February 28, 2022

Karyopharm Announces Changes to Its Clinical Leadership Team

February 21, 2022

Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress

February 7, 2022

Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer

February 7, 2022

Karyopharm Receives Orphan Drug Designation from FDA for Eltanexor for the Treatment of Myelodysplastic Syndromes

January 23, 2022

Karyopharm Promotes Sohanya Cheng to Chief Commercial Officer

January 9, 2022

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Net Product Revenues and Outlines 2022 Objectives

January 9, 2022

Calls in 2022

Decks in 2022